All In Biotech

Drug Trial Radar · NCT02580370

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Last checked: Nov 20, 2026Latest source record: Sep 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Sep 2015

Primary completion

Jul 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.

Conditions

  • Skin Aging

Interventions

  • Botulinum toxin type ABiological

    Topical botulinum toxin type A

  • Placebo comparatorBiological

    Topical placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite endpoint based upon the investigator global assessment (IGA-LCL) and patient assessment of severity (PSA) of lateral canthal linesTime frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Coral Gables, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.